Positron emission tomography (PET Tracer) imaging with 68Ga-pentixafor is an effective diagnostic tool for the central nervous system (CNS) B-cell lymphoma, according to a proof-of-concept study. Targeting the CXCR4 biomarker involved in the growth, survival, and dissemination of aggressive B-cell lymphoma, 68Ga-pentixafor PET imaging shows excellent contrast characteristics between lymphoma lesions and surrounding healthy brain tissue and may be suitable for risk stratification and response assessment.
CNS B-cell lymphoma is a rare malignancy that has several clinical challenges, including diagnosis, risk stratification, and optimization of treatment. Magnetic resonance imaging (MRI) is the current standard imaging technology for this disease, and while it provides high sensitivity, it offers only moderate specificity. Novel molecular and functional imaging strategies are urgently required for this patient population.
CXCR4-directed PET tracer imaging with 68Ga-pentixafor could not only facilitate diagnostic work-up and response assessment but could also serve as a biomarker for selecting patients with a dismal prognosis who could benefit from more intense treatment options. CXCR4-targeted theranostics thus moves nuclear medicine further on the track toward biomarker-informed molecular medicine.